- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | Alpha Teknova, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.03. | Earnings call: Teknova anticipates modest growth amid cost savings | 1 | Investing.com | ||
| 11.03. | Recap: Alpha Teknova Q4 Earnings | 1 | Benzinga.com | ||
| 11.03. | Alpha Teknova GAAP EPS of -$0.26 misses by $0.02, revenue of $7.9M misses by $0.42M | 1 | Seeking Alpha | ||
| 11.03. | Alpha Teknova, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.03. | Alpha Teknova, Inc.: Teknova Reports Fourth Quarter and Full Year 2023 Financial Results | 171 | GlobeNewswire (Europe) | Full year 2023 total revenue was $36.7 million, down 11% year-over-yearAchieved 36% annual growth in the number of Clinical Solutions customers in 2023Company provides 2024 revenue guidance of $35-38... ► Artikel lesen | |
| 21.02. | Alpha Teknova, Inc.: Teknova to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024 | 1 | GlobeNewswire (USA) | ||
| 16.01. | Alpha Teknova, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.11.23 | Alpha Teknova, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.11.23 | Alpha Teknova GAAP EPS of -$0.34 misses by $0.05, revenue of $8.2M misses by $0.04M | 1 | Seeking Alpha | ||
| 09.11.23 | Alpha Teknova: Q3 Earnings Insights | 1 | Benzinga.com | ||
| 09.11.23 | Alpha Teknova, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.11.23 | Alpha Teknova, Inc.: Teknova Reports Third Quarter 2023 Financial Results | 316 | GlobeNewswire (Europe) | Raised $22.9 million of equity capital, paid down $10.0 million of long-term debtThird quarter 2023 total revenue was $8.2 million, down 24% from prior yearExpect 2023 revenue at the low end of previously... ► Artikel lesen | |
| 10.08.23 | Alpha Teknova, Inc.: Teknova Reports Second Quarter 2023 Financial Results | 1.383 | GlobeNewswire (Europe) | Second quarter 2023 total revenue was $11.5 million, up 26% sequentiallyReceived certification of new state-of-the-art facility for production of GMP-grade productsCompany revises 2023 revenue guidance... ► Artikel lesen | |
| 10.05.23 | Alpha Teknova, Inc.: Teknova Reports First Quarter 2023 Financial Results | 566 | GlobeNewswire (Europe) | First quarter 2023 total revenue was $9.1 million, up 16% sequentially Launch of proprietary AAV-Tek Solutions gene therapy product line Company reaffirms 2023 revenue guidance of $42-46 million HOLLISTER... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,580 | -3,07 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,850 | +1,19 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,780 | 0,00 % | Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products | IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,600 | 0,00 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,030 | +4,04 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,840 | 0,00 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
| ARCTURUS THERAPEUTICS | 26,170 | -3,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,785 | 0,00 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,640 | -0,23 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,730 | +0,14 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,630 | -5,10 % | How Vir found the one: CEO Marianne De Backer | ||
| VERVE THERAPEUTICS | 6,220 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,090 | -2,06 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 2,635 | 0,00 % | Bio-Path files to sell 484K shares of common stock for holders | ||
| BIOMEA FUSION | 10,470 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
ALPHA TEKNOVA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,58 % bei einem Aktienkurs von 1,720 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
